Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in MASLD
NCT06140953Phase 2Completed
- Sponsor
- October 6 University
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trimetazidine in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by October 6 University. Started Dec 2023; status: completed.
02
Drugs
trimetazidine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06140953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140953.